Aquestive Therapeutics Stock (NASDAQ: AQST)

Aquestive Therapeutics (NASDAQ:AQST) Stock, Quote.Headers.trade-ideas

Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Allergy,Food,Concept.,Food,On,Wooden,Table

Biotech

News

Health Care

General

AQST

Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic reactions.

Oral Allergy Medication For Emergencies - Aquestive Therapeutics&#39; Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows

Image16

Intraday Update

Markets

Movers

Trading Ideas

ALLY

APOG

CLSK

CRML

FBLG

HUMA

IRDM

SNAP

Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday

Penny Stocks

Small Cap

ABIO

ACHL

ADXN

ALUR

AXTI

CADL

CASA

DXYZ

EFTR

EIGR

ENPH

FAAS

FLGC

GCTS

GRRR

HUBS

Kintara Therapeutics, Inc. - Common Stock

KTRA

KYCH

LEVI

LGVC

MGNX

MSTR

Nuveen California Dividend Advantage Municipal Fund 2

ONMD

PARA

RELI

RENT

SLNA

SMXT

SPWH

STAA

TCBP

TVGN

VIEW

VSTE

XTIA

ZETA

Shares of  STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance.

STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics Inc

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

Israeli Air Strike Hits Southern Suburbs Of Lebanese Capital

Wells Fargo analyst Donald Fandetti downgrades Ares Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRE#NYSE">ACRE</a>) from Equal-Weight to Underweight and lowers the price target from $7.5 to $7.

Downgrades

Price Target

Analyst Ratings

ACRE

Wells Fargo Downgrades Ares Comml Real Est to Underweight, Lowers Price Target to $7

RBC Capital analyst Ken Herbert maintains MDA Space (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MDA#TSX">MDA</a>) with a Outperform and raises the price target from C$18 to C$20.

TSX:MDA

RBC Capital Maintains Outperform on MDA Space, Raises Price Target to C$20

Evercore ISI Group analyst Chirag Ved maintains Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) with a Outperform and lowers the price target from $33 to $28.

CFLT

Evercore ISI Group Maintains Outperform on Confluent, Lowers Price Target to $28

WHLR

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Wells Fargo analyst Donald Fandetti downgrades Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) from Equal-Weight to Underweight and announces $8 price target.

CMTG

Wells Fargo Downgrades Claros Mortgage Trust to Underweight, Announces $8 Price Target

Evercore ISI Group analyst Mark Mahaney maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Outperform and raises the price target from $225 to $240.

AMZN

Evercore ISI Group Maintains Outperform on Amazon.com, Raises Price Target to $240

RBC Capital analyst James McGarragle reiterates NanoXplore (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GRA#TSX">GRA</a>) with a Outperform and maintains C$3.25 price target.

Reiteration

TSX:GRA

RBC Capital Reiterates Outperform on NanoXplore, Maintains C$3.25 Price Target

Source: <a href="https://www.streetwisereports.com/article/2024/09/18/exploration-co-appoints-renowned-exploration-geologist-as-adviser.html?utm_medium=feed">Streetwise Reports 09/18/2024</a>
This mining professional was involved in discovering and delineating a 30 billion pound copper resource in Panama. Read on to learn more about him.
Prosper Gold Corp. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/pgxff#OTC">PGXFF</a>) appointed Colin Burge, a retired exploration geologist with a 30-year career, as an adviser to the company starting immediately, it announced in a news release.
&quot;Colin brings a wealth of porphyry knowledge and expertise to our team&quot; President and Chief Executive Officer Peter Bernier said in the release. &quot;We look forward to Colin&#39;s expert engagement and assistance in guiding exploration at the Cyprus project and future development opportunities for the company.&quot;
Burge&#39;s expertise lies in discovering and delineating porphyry copper and volcanogenic massive sulfide (VMS) deposits, mostly using geophysical techniques.
Discovery-oriented Burge was part of Inmet Mining Corp.&#39;s corporate development team that led on-site geological activities that resulted in the discovery and delineation of 30,000,000,000 pounds of copper at the Cobre Panama project in Panama. Subsequently, First Quantum Minerals Ltd. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/fqvlf#OTC">FQVLF</a>) acquired Inmet for US$5 billion (US$5B) in 2013.
Previously, Burge managed exploration activities at the Cayeli copper-rich VMS deposit in northeast Turkey and conducted project work in Peru, Australia, Nevada, and Greece for various companies, including Falconbridge Copper Ltd. in British Columbia. He has a bachelor of earth science degree from the University of Waterloo.
Since retiring in 2016, Burge has been evaluating properties for senior and junior mining companies in Canada and the U.S.
In another news announcement in the release, Prosper granted 150,000 stock options to its chief financial officer and an aggregate of 350,000 options to certain of the company&#39;s advisers and employees. Options may be exercised over the next years at CA$0.15 per share. They will vest equally every six months over a two-year period.
<h2>District-Scale Exploration</h2>
Prosper Gold, headquartered in Vancouver, British Columbia (B.C.), is a minerals explorer concentrating on porphyry copper-gold and high-grade gold vein systems, according to its website. Modeled after its predecessor Richfield Ventures, bought out after defining a multimillion-ounce resource, Prosper pursues &quot;the right type of projects at the right time in an improving market.&quot;
The company has two district-scale exploration projects in Canada: Cyprus in north-central B.C. and Golden Sidewalk in northwestern Ontario
Cyprus, the focus of a current exploration program, is a porphyry copper-gold project comprising 623 square kilometers (623 sq km) of contiguous claims in part of an Eocene porphyry belt. It is on trend with American Eagle Gold Corp.&#39;s (OTC: <a class="ticker" href="https://www.benzinga.com/stock/amegf#OTC">AMEGF</a>) NAK Project, 60 km to the south in the same metallogenic belt, Technical Analyst Clive Maund reported in an Aug. 16 report.*
<img alt="" class="float_left" src="https://www.theaureport.com/images/auto_up/202491853055_1.png" style="height:577px; width:1000px" />
The three known copper prospects at Cyprus are Kaza, Northstar, and Big-Time. Historically, the property showed 138 meters (138m) of 0.55% copper. Most recently, a property-wide ZTEM survey was conducted, which outlined six high-priority porphyry copper-gold targets, named Targets A through F, undercover, in areas with little to zero outcrop. They were shown to have multikilometer footprints extending to depth.
Of the sextet, Target A is the highlight as it &quot;represents a very attractive porphyry target.&quot; Next to a regional fault, Target A is a 2-by-4 km conductivity anomaly coinciding with a pronounced magnetic low.
&quot;The recent ZTEM (Z‐Tipper Axis Electromagnetic) survey results are encouraging given the characteristics of the anomalies and the presence of copper-gold mineralization elsewhere on the project&quot; Burge said in the release.
Prosper&#39;s Golden Sidewalk is an Archean orogenic gold project covering 160 sq km of contiguous mineral claims and mining leases in the western Birch-Uchi Greenstone belt, about 60 km east of Ontario&#39;s Red Lake. Three mineralized trends have been identified at the property.
The Canadian exploration company also boasts &quot;an experienced and outstanding management team&quot; as described by Maund. CEO Bernier at Richfield Ventures delineated a significant bulk tonnage deposit whose initial resource estimate was 4,200,000 ounces of gold in the Indicated and Inferred categories. New Gold Inc. (AMEX:NGD) acquired Richfield in 2011 for US$550 million.
&quot;The fact that people like Peter Bernier are on the management team of Prosper Gold means that there is a very good chance of it making a significant discovery or discoveries, for the simple reason that if it didn&#39;t, he probably wouldn&#39;t be there&quot; Maund wrote. &quot;If Peter Bernier can do what he did with Richfield Ventures once, he can do it again.&quot;
<h2>Demand for Copper &quot;Unstoppable&quot;</h2>
The global copper market is expected to grow in value by 2030 to US$259B from US$170B in 2022, according to Statista.
&quot;Copper has become indispensable&quot; Marin Katusa of Katusa Research wrote in a recent article. From electric vehicles to renewable energy systems, its role in the global economy is critical. The ongoing electrification of the world depends heavily on copper, and this dependence is only set to grow.
This is good news for copper exploration companies, particularly those with a copper-gold porphyry deposit. These deposits, according to Investing News Network, are &quot;among the world&#39;s most valuable deposits&quot; because they contain the largest known exploitable concentrations of copper.
INN explained in another article, &quot;Due to their size and scope, copper porphyry deposits have the potential to become large-tonnage, low-cost operations based on mineralization.&quot;
<blockquote class="callOut left">&quot;The strongly positive results from this ZTEM survey make the stock even more of a Buy than it was before&quot; Technical Analyst Clive Maund wrote.</blockquote>
According to Katusa, demand for &quot;the engine of the green economy&quot; is &quot;unstoppable&quot; and a supply crunch is inevitable, as indicated by three metrics.
They are the rapid decline in days of forward consumption of copper, the long-term global market balance for copper moving toward a deficit, and a slowing of global mine production of copper. From 2015 to 2023, only 18,000,000 (18 Mt) of copper were discovered versus 28 Mt in 2014 alone.
While demand for the red metal is increasing, supply remains constrained. Joe Austin, senior analyst at Chaikin Analytics, reported that the copper supply is expected to start declining after peaking at some point in the next two years, according to the International Energy Agency. The agency estimates a copper shortfall of about 7 Mt by 2035, about a third of the output forecasted for that year.
&quot;By 2040, the available supply of copper will be roughly two-thirds of what we produce today. But by then, the demand for copper will have soared far higher than where it is today&quot; Austin wrote.
This anticipated tightening of the copper market is likely to cause a price surge, Katusa purported. In fact, the outlook for the copper price, important for Prosper Gold, is favorable, Maund wrote on Sept. 10.
&quot;The recent reaction appears to have run its course&quot; noted the analyst. &quot;It now looks like it is shaping up to begin another major uptrend, which is hardly surprising given the huge copper supply deficit that is right now starting to bite and is set to get a lot worse as this decade unfolds.&quot;
<h2>The Catalyst: Exploration Progress</h2>
Along with the now completed ZTEM survey, the work planned for Prosper&#39;s in-progress 2024 exploration program includes 2,500m of drilling, trenching, and regional exploration, according to the company&#39;s September 2024 Presentation.
The results of any of these components could push up the explorer&#39;s share price.
<h2>Stock is an Immediate Strong Buy</h2>
The stock charts indicate Prosper Gold is positioned now to break out of its consolidation pattern and begin a new upleg, Maund wrote. This anticipated rally could be better than the last one.
Therefore, Maund rated the stock an Immediate Strong Buy for all time horizons and indicated he intends to remain long in it.
&quot;The strongly positive results from this ZTEM survey make the stock even more of a Buy than it was before&quot; he wrote.
<h2>Ownership and Share Structure</h2>
According to the company,17.9% of Prosper Gold is owned by management and insiders. Of those, CEO Peter Bernier owns the most with 12.88% and Director Jason Hynes owns 1.86%.
The rest is with retail investors.
The company presently has 36.7 million free float shares and a market cap of 4.3 million. The 52-week range of Prosper Gold is US$0.06&ndash;$0.15,
Important Disclosures:
Prosper Gold Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports&#39; terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
* Disclosure for the quote from the Clive Maund article published on August 18, 2024
<ol>
<li>For the quoted article (published on August 18), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.</li>
<li>Author Certification and Compensation: [Clive Maund of clivemaund. com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts&#39; Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed</li>
</ol>
Clivemaund .com Disclosures
The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund&#39;s opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund&#39;s opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

Large Cap

Mid Cap

Management

AMEGF

FQVLF

PGXFF

Exploration Co. Appoints Renowned Exploration Geologist as Adviser

Wells Fargo analyst Donald Fandetti upgrades Annaly Capital Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLY#NYSE">NLY</a>) from Equal-Weight to Overweight and raises the price target from $19 to $23.

Upgrades

Wells Fargo Upgrades Annaly Capital Management to Overweight, Raises Price Target to $23

The most oversold stocks in the financials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Netcapital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>)</h3>
<ul>
<li>On Sept. 16, Netcapital posted a first-quarter loss of $5.10 per share. &#8220;This was a challenging quarter for us, driven primarily by a decrease in revenues for services that we provide in exchange for equity securities,&#8221; said Martin Kay, CEO of Netcapital Inc. &#8220;However, we have taken what we believe are important steps to lay the groundwork for future opportunities.&#8221; The company's stock fell around 40% over the past five days and has a <a href="https://www.benzinga.com/quote/GTE">52-week low of $1.54</a>.</li>
<li>RSI Value: 29.24</li>
<li>NCPL Price Action: Shares of Netcapital fell 5.2% to close at $1.63 on Thursday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">latest NCPL news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="845" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045714/image-158.png" alt="" class="wp-image-557860" style="width:598px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045714/image-158.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045714/image-158-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045714/image-158-768x716.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Reliance Global Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Sept. 9, Reliance Global Group provided an update on the pending acquisition of Spetner Associates, including a significant reduction in the upfront cash payment required to close the transaction. The company's stock fell around 11% over the past five days. It <a href="https://www.benzinga.com/quote/VIVK">has a 52-week low</a> of $2.12.</li>
<li>RSI Value: 27.09</li>
<li>RELI Price Action: Shares of Reliance Global fell 5.8% to close at $2.45 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">trend in RELI stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045734/image-159.png" alt="" class="wp-image-557861" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045734/image-159.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045734/image-159-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045734/image-159-768x697.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Kaspi.kz AO &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>)</h3>
<ul>
<li>On Sept. 19, Culper Research issued a report on the company. The company's shares fell around 21% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/KSPI">low of $85.02</a>.</li>
<li>RSI Value: 18.65</li>
<li>KSPI Price Action: Shares of Kaspi.kz AO fell 16.1% to close at $99.81 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">breakout in KSPI shar</a>es. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="883" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045802/image-160.png" alt="" class="wp-image-557862" style="width:642px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045802/image-160.png 883w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045802/image-160-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20045802/image-160-768x732.png 768w" sizes="(max-width: 883px) 100vw, 883px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Long Ideas

Pre-Market Outlook

KSPI

NCPL

Top 3 Financials Stocks That May Rocket Higher This Quarter

RBC Capital analyst Andrew Wong reiterates Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Outperform and maintains $60 price target.

RBC Capital Reiterates Outperform on Nutrien, Maintains $60 Price Target

The Nasdaq 100 closed higher by around 2.5% during Thursday's session. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Bentley Systems</h3>
<ul>
<li>The Trade: Bentley Systems, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) Chief Product Officer Michael M Campbell <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 4,578 shares</a> at an average price of $47.27. The insider received around $216,416 from selling those shares.</li>
<li>What's Happening: On Sept. 16, Rosenblatt analyst Blair Abernethy maintained Bentley Systems with a Buy and maintained a $62 price target.</li>
<li>What Bentley Systems Does: Bentley Systems is a software vendor that caters to engineers, architects, constructors, and geospatial professionals by enabling design, modeling, simulation and project, and data management of infrastructure assets.</li>
</ul>
<h3 class="wp-block-heading">Clean Harbors</h3>
<ul>
<li>The Trade: Clean Harbors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLH#NYSE">CLH</a>) Director Lauren States <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 309 shares</a> at an average price of $244.09. The insider received around $75,424 from selling those shares.</li>
<li>What's Happening: On July 31, Clean Harbors reported better-than-expected second-quarter financial results and raised its FY24 adjusted EBITDA guidance.</li>
<li>What Clean Harbors Does: Clean Harbors Inc is an environmental and industrial services provider.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40952252/nvidia-tesla-rally-as-dow-s-p-500-surge-to-fresh-highs-after-fed-cuts-rates-fear-index-remains-in-g">Nvidia, Tesla Rally As Dow, S&amp;P 500 Surge To Fresh Highs After Fed Cuts Rates: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Short Ideas

Insider Trades

Bentley Systems And 1 Other Stock Executives Are Selling

Novo Nordisk Reports Results From Phase 2a Trial Of Monlunabant In Obesity, Showing Significant Weight Loss And Plans Phase 2b Trial In 2025

Wells Fargo analyst Donald Fandetti upgrades AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) from Equal-Weight to Overweight and raises the price target from $10 to $12.

AGNC

Wells Fargo Upgrades AGNC Investment to Overweight, Raises Price Target to $12

LAES

SEALSQ Integrates Internet of Payment In IoT-Enabled Semiconductors

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>). &#8220;This is a really fine company, and it will do well for multiple years because they have many <a href="https://www.benzinga.com/quote/VKTX/news">ships coming in,&#8221; he added.</a>
On Sept. 11, JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.
Gentex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is &#8220;too closely related to autos, and autos have been hurt so bad. And I don't see a quick turn. We're going to need several Fed rate cuts before they turn,&#8221; Cramer said.
On July 26, the company reported second-quarter earnings per share of 37 cents, but it missed the street view of 52 cents. Quarterly sales of $572.93 million missed the analyst consensus of $622.79 million.
The Mad Money host said Cadre Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is a &#8220;good simple story.&#8221;
On Aug. 9, Cadre Hldgs reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $144.31 million which beat the analyst consensus estimate of $142.05 million.
&#8220;Something's the matter with Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>),&#8221; Cramer said. &#8220;I want to know what's wrong.&#8221;
On Sept. 19, Celsius Holdings appointed Hans Melotte to the company&#8217;s Board of Directors.
Price Action:
<ul>
<li>Viking shares gained 5.8% to settle at $68.16 on Thursday.</li>
<li>Gentex shares gained 1.8% to close at $29.82 during the session.</li>
<li>Cadre shares gained 2.4% to close at $37.36 during Thursday's session.</li>
<li>Celsius shares fell 0.6% to settle at $34.07 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40948972/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>

Media

CDRE

CELH

GNTX

VKTX

Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'

Scotiabank analyst Andres Coello downgrades Telecom Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEO#NYSE">TEO</a>) from Sector Perform to Sector Underperform and raises the price target from $5.7 to $6.1.

Telecom Argentina Stet - France Telecom S.A.

Scotiabank Downgrades Telecom Argentina to Sector Underperform, Raises Price Target to $6.1

As the cannabis and hemp industries continue to expand, the regulation of hemp-derived products, such as Delta-8 THC, has become a focal point of debate. Pablo Zuanic, a highly-respected equity analyst following the cannabis and psychedelics industries and an upcoming speaker at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Captial conference</a>, addressed the future of hemp derivatives during a recent interview. 
With evolving state regulations and increasing market share, Zuanic said that these products are becoming a permanent part of the industry.
<h3 class="wp-block-heading">Hemp's Growing Role in the Market</h3>
Hemp-derived products have rapidly gained popularity, leading to a highly fragmented market with various players across the supply chain. Zuanic explained the widespread presence of hemp derivatives in the U.S. market. "Hemp derivatives are here to stay," he said. He described the hemp industry as "a very democratic industry, a very competitive capitalist industry" due to its diverse components, including farmers, processors, and manufacturers.
Although hemp-derived products like Delta-8 THC were not originally intended to become such a large part of the market under the 2018 Farm Bill, Zuanic noted that these products have taken on a significant role. "It's not a small little loophole. It's a big thing. It's a big industry," he said, emphasizing the unexpected growth of the hemp derivatives market.
<h3 class="wp-block-heading">Regulation Is on the Horizon</h3>
While hemp-derived products continue to thrive, Zuanic highlighted the growing need for regulatory oversight. He pointed to the current patchwork of state regulations, with some states attempting to enforce stricter controls on producing and selling hemp products. For instance, Florida's governor vetoed a ban on hemp derivatives, but the state still enforces regulations around testing and packaging.
Zuanic said that the disparity in regulations between the hemp and cannabis industries has created an uneven playing field. "It's not a level playing field with the cannabis industry," he said, pointing out how cannabis businesses face much stricter federal and state regulations. 
Zuanic believes that as regulation evolves, both industries will be able to coexist in a more regulated environment. Over the next four years, regulations will probably be established to allow both industries to coexist, he added.
<h3 class="wp-block-heading">A Long-Term Outlook</h3>
As the market for hemp-derived products matures, it is clear that these products will continue to play a major role in the cannabis space. Zuanic's insights offer a realistic view of the industry's future, where hemp derivatives are more tightly regulated but remain an important market segment.
With Zuanic set to speak at the upcoming <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> in Chicago on October 8-9, his thoughts on hemp and cannabis regulation will likely inform discussions among industry leaders about how the two markets can evolve together.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly from top executives, investors, advocates, and policymakers at the 19th <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference </a>in Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40949093/cannabis-multi-state-operator-ayr-wellness-seeks-new-ceo-after-david-gouberts-departure-next-pha">Cannabis Multi-State Operator Ayr Wellness Seeks New CEO After David Goubert&#8217;s Departure: &#8216;Next Phase Of Growth&#8217; Coming?</a></li>
</ul>
Image: Shutterstock

Cannabis

Hemp-Derived Products Like Delta-8 THC Are 'Here To Stay,' Says Analyst

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">relatively flat in the premarket session on Friday.</a>
The Chinese EV maker has denied rumors about plans to take over the Audi Brussels car plant in Vorst, reported CnEV Post.
Yesterday, NIO was in the headlines after media reports emerged that the NIO delegation visited the Vorst plant in recent weeks and working on a bid to <a target="_blank" href="https://www.benzinga.com/news/24/09/40935394/chinese-ev-maker-nio-eyes-audis-brussels-plant-amid-european-expansion-report" rel="noreferrer noopener">submit to Audi parent Volkswagen by next Monday.</a>
This was&nbsp;reported&nbsp;by the Belgian newspaper&nbsp;De Tijd. Belgium-based&nbsp;D&#8217;Ieteren is also interested in the plant, the report said.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40946478/chinas-nio-says-40-of-its-store-managers-are-ex-tesla" rel="noreferrer noopener">China&#8217;s NIO Says 40% Of Its Store Managers Are Ex-Tesla</a>
These speculations generated significant discussion, but the company has clarified that it has no intentions to pursue such a takeover.
Audi&#8217;s parent company, Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VLKAF#OTC">VLKAF</a>), has reportedly decided to cease car production in Vorst after the last Q8 e-tron electric SUV is completed next year.
NIO stated that it had no intentions of taking over the Audi plant, with founder, chairman, and CEO William Li emphasizing that the company was cautious about investing in fixed assets, aside from battery swap stations, CnEV report noted.
CnEV quoted Li as saying, &#8220;How can NIO afford a factory that Audi can&#8217;t afford? (The rumors) are groundless.&#8221;
In Europe, NIO&#8217;s vehicles are presently offered in Norway, Germany, the Netherlands, Sweden, and Denmark, but the company has not initiated sales in Belgium.
Price Action: NIO shares are trading lower by 0.56% to $5.370 premarket at last check Friday.
Photo by Sundry Photography on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40925180/teslas-chinese-competitor-nio-begins-deliveries-of-new-es8-in-europe-amid-eu-tariff-concerns-rep" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Chinese Competitor NIO Begins Deliveries Of New ES8 In Europe Amid EU Tariff Concerns: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

VLKAF

VWAGY

NIO Denies Audi Plant Takeover Rumors: Report

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price target of $9...

Buy Rating Affirmed for Aquestive Therapeutics as Anaphylm™ Poised to Transform Epinephrine Market

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings

An announcement from Aquestive Therapeutics ( ($AQST) ) is now available. Aquestive Therapeutics, Inc. has shared an investor presentation outlinin...

Aquestive Therapeutics Outlines Growth and Product Progress

Aquestive Therapeutics (AQST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on September 11. Analyst Roa...

Aquestive Therapeutics: A Buy Rating on Underappreciated Market Potential and Innovative Pipeline

Small-cap stocks have climbed recently. Here are the ones most poised for further upside

28 Top rated U.S. growth stocks month-to-date in anticipation of Fed cuts

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names per SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names in SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut: See top 20 names in SA Quant ratings

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Aquestive Therapeutics

Aquestive Therapeutics (AQST) Forecast

Aquestive Therapeutics (NASDAQ:AQST) Stock, Quote.Headers.trade-ideas